Abstracts tagged "quality and rheumatoid arthritis (RA)"

Abstract Number: 323 • 2018 ACR/ARHP Annual Meeting
Impact of Gains in Rheumatoid Arthritis Disease Activity Documentation on Outcomes over Time
Jing Li¹, Julie Gandrup¹, Laura Trupin¹, Zara Izadi², Jinoos Yazdany¹ and Gabriela Schmajuk³, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ³San Francisco VA Medical Center, San Francisco, CA
Background/Purpose: Despite significant interest in using health information technology (IT) to improve processes of care such as documentation of disease activity in RA, few studies…
Abstract Number: 2638 • 2015 ACR/ARHP Annual Meeting
Multiple Psychosocial Factors Influence Subjective Assessments of Disease Activity in Rheumatoid Arthritis
Ying L. Liu¹, Joan M. Bathon^2,3 and Jon T. Giles⁴, ¹Internal Medicine, Columbia University Medical Center, New York, NY, ²Medicine, Columbia University, College, New York, NY, ³Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁴Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY
Background/Purpose: Measuring disease activity in rheumatoid arthritis (RA) is important in evaluating efficacy of treatments, but many tests are subjective and lead to discordance in…
Abstract Number: 941 • 2014 ACR/ARHP Annual Meeting
Biologic De-Escalation in Rheumatoid Arthritis: Cost Savings and Clinical Success
Tarun S. Sharma¹, Lyudmila Kirillova², Andrea Berger³ and Eric D. Newman⁴, ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Rheumatology, Geisinger Health System, Danville, PA, ³Center for Health Research, Geisinger Health System, Danville, PA, ⁴Department of Rheumatology, Geisinger Health System, Danville, PA
Background/Purpose: Economic considerations and clinical risks of prolonged biologic use in Rheumatoid Arthritis (RA) have emerged as concerns. In this study, we measured the clinical…
Abstract Number: 2254 • 2013 ACR/ARHP Annual Meeting
Complementary and Alternative Medicine in Rheumatoid Arthritis – Persistently High Use Over the Past Decade Despite Advent of Biologics
Dana DiRenzo^1,2, Haiyan Sun³, H. Lester Kirchner³ and Eric D. Newman⁴, ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Internal Medicine, University of Maryland Medical Center, Baltimore, MD, ³Geisinger Center for Health Research, Geisinger Health System, Danville, PA, ⁴Department of Rheumatology, Geisinger Health System, Danville, PA
Background/Purpose: Complementary and Alternative Medicine (CAM) is commonly used when traditional medicine cannot reliably alter the disease. Over the past decade, rheumatoid arthritis (RA) treatment…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.